Video
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
VIDEO: CPX-351 ‘new standard of care’ for older patients with secondary AML
- Author:
- Mary Jo Dales
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_110b00f5b7b9e44433_McCarthy_Philip_NY.jpg)
Lenalidomide maintenance prolongs overall survival after ASCT
- Author:
- Mary Jo Dales
Lenalidomide maintenance therapy significantly prolonged overall survival after autologous stem cell transplant in newly diagnosed multiple...
News
Up-front ASCT superior for fit patients with newly diagnosed myeloma
- Author:
- Mary Jo Dales
Upfront high-dose melphalan and autologous stem cell transplantation was superior to bortezomib-melphalan-prednisone for fit patients under age 65...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_97166380f22720e45e_FDA_icon.jpg)
Ocaliva approved for primary biliary cholangitis
- Author:
- Mary Jo Dales
News
Venetoclax achieves responses in CLL refractory to ibrutinib, idelalisib
- Author:
- Mary Jo Dales
Key clinical point: Venetoclax can achieve responses in patients who are refractory to ibrutinib. Major finding: The overall response rate was 61...
Video
![](https://qa00.mdedge.com/sites/all/modules/contrib/lazyloader/image_placeholder.gif)
VIDEO: Adding ixazomib to len-dex boosts progression-free survival in multiple myeloma
- Author:
- Mary Jo Dales
Key clinical point: Adding ixazomib to lenalidomide and dexamethasone was associated with a longer progression-free survival and limited...
News
New single-tube assay detects one CLL cell in 1 million leukocytes
- Author:
- Mary Jo Dales
Key clinical point: Chronic lymphocytic leukemia cells can be identified at levels as low as 0.0010% with a newly developed and validated single-...
News
In severe hemophilia B, rIX-FP prophylaxis gets good results with less frequent dosing
- Author:
- Mary Jo Dales
Key clinical point: Weekly and 14-day prophylaxis regimens with rIX-FP were well tolerated and provided low bleeding rates and target joint...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_d595f9a1fae0c3acb1_leukemia_acutelymphoblastic.jpg)
Prelabor cesarean delivery linked to increased risk of childhood ALL
- Author:
- Mary Jo Dales
Key clinical point: Prelabor cesarean delivery was associated with an increased risk of childhood ALL, but not AML. Major finding: The odds ratio...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_bf0698967bbf68499a_FISH_lymphocyte.jpg)
In newly diagnosed CLL, mutation tests are advised
- Author:
- Mary Jo Dales
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_90893413b2042190e1_Garcia_Manero_Guillermo_0.jpg)
Rigosertib falls short for high-risk myelodysplastic syndromes after failure on azacitidine or decitabine
- Author:
- Mary Jo Dales
Key clinical point: Rigosertib failed to extend overall survival beyond that seen with best supportive care in a trial of patients who had...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_90893413b2042190e1_Garcia_Manero_Guillermo.jpg)
Rigosertib falls short for high-risk myelodysplastic syndromes after failure on azacitidine or decitabine
- Author:
- Mary Jo Dales
Key clinical point: Rigosertib failed to extend overall survival beyond that seen with best supportive care in a trial of patients who had...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_18280301e2d47a4321_Press_Oliver.jpg)
FDG-PET guides need for eBEACOPP in advanced Hodgkin’s
- Author:
- Mary Jo Dales
Key clinical point: Using FDG-PET imaging to gauge treatment response after the first two rounds of ABVD therapy helps to determine which patients...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_c283b742690a04bacb_lymphoma_diffuse_large_B_cell.jpg)
CUDC-907 enters phase II for relapsed or refractory lymphoma and multiple myeloma
- Author:
- Mary Jo Dales
Key clinical point: The CUDC-907 dose to be used in phase II studies will be 60 mg on a 5-days-on/2-days-off dosing schedule. Major finding: Two...
News
![](https://cdn-uat.mdedge.com/files/s3fs-public/styles/max_width_small/public/images/article_teasers/media_8f08ea5309010b4bde_FDA_icon.jpg)
FDA approves venetoclax for CLL with 17p deletion
- Author:
- Mary Jo Dales